Literature DB >> 10489980

18 years mitotane therapy for intractable Cushing's disease.

S Kawai, Y Ichikawa, J Kaburaki, T Yoshida.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10489980     DOI： 10.1016/S0140-6736(05)75699-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  5 in total

1.  A six month mitotane course induced sustained correction of hypercortisolism in a young woman with PPNAD and Carney complex.

Authors:  M Cignarelli; G Picca; M Campo; M Margaglione; A Marino; F Logoluso; F Giorgino
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

Review 2.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

Review 3.  Cushing's disease.

Authors:  Martina De Martin; Francesca Pecori Giraldi; Francesco Cavagnini
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

Review 4.  Recent developments in drug therapy for Cushing's disease.

Authors:  Rob van der Pas; Wouter W de Herder; Leo J Hofland; Richard A Feelders
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

5.  Mitotane (op'DDD) restores growth and puberty in nine children with Cushing's disease.

Authors:  Emmanuelle Motte; Anya Rothenbuhler; Stephan Gaillard; Najiba Lahlou; Cécile Teinturier; Régis Coutant; Agnès Linglart
Journal:  Endocr Connect       Date:  2018-12       Impact factor: 3.335
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.